Related by context. Frequent words. (Click for all words.) 68 phase IIb clinical 68 randomized Phase III 67 prospective multicenter 67 phase IIa 67 Pivotal Phase III 67 Phase Ib clinical 66 Pivotal Trial 66 multicenter clinical 66 double blinded placebo 66 label multicenter 66 Phase 1b clinical 66 phase IIb 66 placebo controlled Phase 65 Multicenter 65 placebo controlled clinical 65 Randomized controlled 65 Phase 2a clinical 65 multicenter Phase 64 nonrandomized 64 multicentre 64 prospective randomized controlled 64 multicenter randomized 64 multicenter randomized double 64 placebo controlled randomized 64 Phase 2b clinical 63 Phase IIB 63 Phase III randomized 63 active comparator 63 MKC# 63 relapsed refractory multiple myeloma 62 exemption IDE 62 Pivotal Phase 62 randomized controlled clinical 62 SPIRIT IV 62 SPIRIT III 62 pharmacokinetic PK 62 dose escalation trial 62 confirmatory Phase III 62 Phase III Clinical Trial 62 Phase III pivotal 62 phase 2a 61 PRECiSE 61 SAR# [004] 61 Phase Ib 61 label dose escalation 61 Phase III clinical 61 elotuzumab 61 Phase 1b trial 61 pivotal Phase III 61 Completes Enrollment 61 blinded placebo controlled 61 Phase III 61 Phase IIa clinical 61 Phase IIb 60 Presents Positive 60 Phase Ia 60 TRITON TIMI 60 Acute Myocardial Infarction 60 R sorafenib tablets 60 Phase 1b 60 PROPEL trial 60 Investigational Device Exemption IDE 60 Pirfenidone 60 Amrubicin 60 Phase 2a trial 60 Phase 2a 60 Phase 1a 60 Phase IIa trial 60 IIa trial 60 Investigational Device Exemption 60 pharmacokinetics PK 60 Phase 2b study 60 Phase IIb clinical 60 ILLUMINATE 60 Percutaneous Coronary Intervention 60 Tesetaxel 59 confirmatory Phase 3 59 budesonide MMX 59 registrational 59 single ascending dose 59 PRECISE 59 Phenoptin 59 multicenter 59 OncoVEX GM CSF 59 metastatic hormone refractory 59 prospectively defined 59 Coronary Stent 59 substudy 59 Clinical Trial Results 59 Phase III Trial 59 pulmonology portfolio 59 Stedivaze 59 relapsing multiple sclerosis 59 GV# [001] 59 liposomal formulation 59 StemEx 59 interferon beta 1b 59 axitinib 58 Traficet EN 58 forodesine 58 http:/www.clinicaltrials.gov